RTP Mobile Logo
Prostate Cancer Update, Issue 1, 2011
Released November 2011

Featuring interviews with Drs E David Crawford, Christopher J Logothetis, Robert Dreicer and Allan Lipton. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    An estimated 220,000 new cases of prostate cancer are diagnosed yearly in the United States and account for approximately one third of new cancer cases among men. Published results from clinical trials lead to the emergence of new local and systemic therapeutic approaches, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. By providing information on the latest research developments and expert perspectives, this CME activity assists clinicians with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Develop a rational evidence-based approach to the use of bone-targeted therapies for patients with early and advanced-stage prostate cancer.
    • Counsel patients with metastatic castration-resistant prostate cancer (mCRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life.
    • Compare and contrast the efficacy, safety and tolerability of evidence-based chemotherapy and immunotherapy for patients with mCRPC.
    • Recognize the contribution of symptoms and tumor burden in the decision to employ sipuleucel-T in the treatment of mCRPC.
    • Explore the emerging data and active research evaluating novel agents — including tyrosine kinase inhibitors, radiopharmaceuticals, androgen biosynthesis inhibitors and antiandrogens — in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity.
    • Recall pivotal Phase III findings with abiraterone acetate in chemotherapy-pretreated CRPC.
    • Counsel appropriately selected patients with biochemically recurrent, asymptomatic or symptomatic metastatic prostate cancer about availability of and participation in ongoing clinical trials.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr CrawfordAdvisory Committee: Centocor Ortho Biotech Services LLC, Ferring, GlaxoSmithKline, Sanofi; Employee (Wife): Ferring; Meeting Participant: Aureon Laboratories Inc. Dr LogothetisPaid Research: Dendreon Corporation, Johnson & Johnson Pharmaceuticals. Dr DreicerAdvisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Centocor Ortho Biotech Services LLC, EMD Serono Inc, GTx Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi; Consulting Agreement: Centocor Ortho Biotech Services LLC. Dr LiptonAdvisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, Novartis Pharmaceuticals Corporation; Paid Research: Amgen Inc, Monogram Biosciences Inc, Novartis Pharmaceuticals Corporation.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Amgen Inc, Astellas Pharma Global Development/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation and Sanofi.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    November 2011
    Expiration date: November 2012

Acknowledge and close

Listen to audio:
Prostate Cancer Update, Issue 1, 2011
Released November 2011

Featuring interviews with Drs E David Crawford, Christopher J Logothetis, Robert Dreicer and Allan Lipton. (Audio Content)

Read print: